Skip to content

Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation

Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients.

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00538265
Acronym
BEFIRTH
Enrollment
100
Registered
2007-10-02
Start date
2005-05-31
Completion date
2011-01-31
Last updated
2011-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Keywords

liver transplantation, hepatitis C virus, immunoprophylaxis

Brief summary

An open-label randomized multicenter clinical study comparing three regimes of immunosuppression : (A) tacrolimus and steroids, (B) antithymocyte induction therapy and full dose of tacrolimus, (C) antithymocyte induction therapy with mycophenolate mofetil and a reduced dose of tacrolimus.

Interventions

DRUGtacrolimus

Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months

DRUGtacrolimus, ATG

immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage. In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids. In this study arm, tacrolimus will be administered as in arm (A)

DRUGATG+mycophénolate mofétil+tacrolimus

immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3. In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months.

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients who received a first liver transplantation, * presenting with a qualitative or quantitative PCR positive for hepatitis C virus at time of transplantation, whatever the transaminase activity, * Women of childbearing potential with a negative pregnancy test, * Male or female patients who agree to use an effective method of contraception, * patients who signed a written informed consent form to participate in the study, * patients who are compliant and likely to follow the visits specified by the study protocol

Exclusion criteria

* • Preoperative serious renal impairment (serum creatinine levels \> 200 µmol/l), * repeat transplantation, * multiple organ transplantation, * transplantation performed with an organ transplant obtained from a living donor or a reduced or shared organ grafts, * serious concomitant disorder, * positive serology for HBs antigen or HIV positive at time of enrollment, * previous history of nonhepatic cancer (except for localized skin cancer), * presence of a hepatocellular carcinoma, for which the primary lesion exceeds 5 cm or is complicated by portal thrombosis or metastatic disease, * an investigational product or therapy administered less than one month before entry into the study.

Design outcomes

Primary

MeasureTime frame
The primary endpoint will be degree of fibrosis = Ishak's histological score of hepatic biopsy at 1 year1 year

Secondary

MeasureTime frame
• Ishak's degree of activity1 year
Ishak's degree of fibrosis2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026